Sartorius Stedim stock: UBS keeps Buy rating at EUR 260.00

Published on 10/21/2026 at 17:17 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

2026 revenue guidance is EUR 3.15 billion. Sartorius Stedim stock costs EUR 213.60 on October 21, 2026, down 0.65 percent versus Xetra close.

Analyst target and reporting date

UBS maintained a Buy rating and a EUR 260.00 target on October 15, 2026.
First-half 2026 revenue was EUR 1.53 billion and the EBITDA margin was 31.40 percent.
Sartorius Stedim stock costs EUR 213.60 at Lang & Schwarz on October 21, 2026 at 5:08 p.m. CEST, 0.65 percent below the Xetra close of October 20, 2026.
The company scheduled its 9M 2026 results conference call for October 22, 2026.

Bauhaus-Plakatdesign mit Schriftzug BIOPROCESS und geometrischen Primärfarben — Sartorius Stedim Biotech Bauhaus-Poster mit Schriftzug BIOPROCESS und farbenfrohen geometrischen Formen, ISIN FR0013154002, Illustration mit AI erstellt.

Sartorius Stedim stock (ISIN FR0013154002) has a Buy rating from UBS and an unchanged EUR 260.00 target, as MarketScreener reported on October 15, 2026. The target is 21.72 percent above the EUR 213.60 price at Lang & Schwarz on October 21, 2026 at 5:08 p.m. CEST, while the stock was down 0.65 percent versus the Xetra close of October 20, 2026 at EUR 215.00.

Revenue and margin remain central

The next operating datapoint is the 9M 2026 update. The company expects fiscal-year 2026 sales revenue growth of 6.00 to 10.00 percent in constant currencies and an underlying EBITDA margin above 31.00 percent, according to its Sartorius Stedim Biotech investor-relations page.

For the first half of 2026, revenue stood at EUR 1.53 billion and the EBITDA margin at 31.40 percent, figures reported by IT BOLTWISE on September 25, 2026. The period gives investors a concrete benchmark for the upcoming update.

Stock stays below its yearly high

The EUR 213.60 quote is EUR 11.40 below the EUR 225.00 52-week high and EUR 63.60 above the EUR 150.00 low, both shown for October 21, 2026. That places the stock 5.07 percent below its yearly high and 42.40 percent above its yearly low.

Market capitalization stood at EUR 20.8 billion on October 21, 2026. The price-to-earnings ratio was 70.73 on the same date, putting valuation attention on whether the coming operating figures can support the 2026 outlook.

Results call is scheduled for October 22

The next dated company event is the 9M 2026 results conference call on October 22, 2026 at 1:00 p.m. CEST, listed on the investor-relations page. The event should provide the next period-specific update on sales, consumables demand, equipment activity and profitability.

Price and target in perspective

UBS's EUR 260.00 target sits EUR 46.40 above the Lang & Schwarz price. The target comparison is separate from the daily move because the latter is calculated against the Xetra close, while the former reflects an analyst valuation view dated October 15, 2026.

At EUR 213.60, Sartorius Stedim remains within its EUR 150.00 to EUR 225.00 52-week range. The company serves biopharmaceutical manufacturers with single-use technologies, filtration, purification and fluid-management solutions, giving the upcoming results a direct read-through for both recurring consumables and equipment demand.

Trading price and next date

Sartorius Stedim was trading at EUR 213.60 at Lang & Schwarz on October 21, 2026 at 5:08 p.m. CEST, down 0.65 percent versus the Xetra close of October 20, 2026 at EUR 215.00. The next company date is October 22, 2026.

The further course of trading is shown by the continuously updated real-time quote of Sartorius Stedim stock.